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Learning 
objectives 
After completing this module students and public health 
professionals should:  
• be aware of new terminology in the EU pharmaceutical field 
since 2004, based on Directive 2004/27/EC; 
• recognise the newly introduced product, which were for first 
tine submitted via European Evaluation Agency – EMEA; 
• increase knowledge of comparison of generics and 
biosimilars; 
• differentiate the groups and the products which are included; 
• identified, upon official sources the  word market of the 
biopharmaceuticals where the patent has already soon 
expired; 
• improve the knowledge and understanding of the largest 
group of proteins derived from biotechnology, blood-plasma 
medicinal products, vaccines, cytokines, interleukins, 
hormones, gene - and cell - therapeutic and in vivo diagnostic 
allergenic products, where the patent  and the data exclusivity 
is expire and  biosimilar product could be authorised. 
Abstract The article presents a legislative overview of the medicinal 
products from biotechnological source, which are derived from 
living organisms so called biosimilars. Since 2004, based on 
Directive 2004/27/EC the term “biogeneric” does not exist any 
more and the therapeutic proteins including, recombinant human 
insulin for the treatment of diabetes, human growth hormone for 
the treatment of hypo-pituitary dwarfism, interferon, 
erythropoietin for the treatment of anaemia in cases of 
 chronic renal failure, various blotting factors referred to an 
original medicinal products are called «boisimilars».  All these 
biological medicinal product often heterogeneous so that modern 
analytical  
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 methodology could not always characterize them in terms of 
differences in conformation, heterogeneity and impurity profiles. 
Since 20 November 2005 the Marketing authorization way for 
biosimilars is via the Centralized Procedure pursuant Regulation 
(EC) 726/2004, Annex 1. In year 2006-2007 the number of the 
submitted medicinal product to  EMEA is 14. The survey follows 
and discusses the issues which are necessary for the marketing 
authorization of all these medicinal products to prove the safety, 
efficacy and quality, where appropriate pre-clinical tests or 
clinical trials relating to these conditions must be provided. 
Teaching 
methods 
Lectures, seminars, exercises, individual work and small group 
discussions.  
Specific 
recommendation
s 
for teachers 
• work under teacher supervision /individual students’ work 
proportion: 30%/70%; 
• facilities: a computer room; 
• equipment: multimedia, LCD projection equipment, 
computers (1 computer on 3 students), internet connection, 
access to bibliographic data-bases; 
• training materials: readings are mainly available in the 
Internet; 
• target audience: master degree students. 
 
Assessment of  
Students 
The final mark should be derived from assessment of the 
theoretical knowledge (oral exam), multiple choice questionnaire 
(MCQ), contribution to the group discussions, quality of 
individual work and seminar paper. 
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THERORETICAL BACKGROUND 
Legislative Background for Marketing Authorisation of the 
Biosimilar Medicinal Product  
Thanks to the development of molecular biology and genetic engineering, new medicinal 
products derived from biotechnology are available to healthcare markets, thanks to the 
recombinant DNA (r-DNA) technology in the last 20 years used to manufacture safe and 
effective therapeutic medicinal products. 
 Medicinal products from biological source are derived from living organisms and 
they are often heterogeneous so that modern analytical methodology could not always 
characterize them in terms of differences in conformation, heterogeneity and impurity 
profiles. These therapeutic proteins include recombinant human insulin for the treatment 
of diabetes, human growth hormone for the treatment of hypo-pituitary dwarfism, 
interferon, and erythropoietin for the treatment of anaemia in cases of chronic renal 
failure, various blotting factors and many other conditions. 
The largest group of proteins derived from biotechnology are, blood-plasma 
medicinal products, vaccines, cytokines, interleukins, hormones, gene - and cell - 
therapeutic and in vivo diagnostic allergenic products, these represent and most of them 
are heterogenic and the contemporary analyses do not provide method for full analyses 
option. Often the analysis method may have product impact. In the last decade the 
medicinal products from biological origin are growing extremely and, the forecast till  
year 2010 will be nearly 50% of all new marketing authorized product will be of 
biotechnological origin (Fig 1 and Fig 2) (1). 
The different patent position for biopharmaceutical is complicated by the fact that 
“biogenerics” does not exists” with the Review 2005. As the regulation stand, 
therapeutically similar products must be different to the original and they cannot rely on 
the original data and must submit full market authorisations via the EMEA’ centralised 
procedure, since 20 November 2005. Many biotech medicinal products are in process or 
are already patent expiry and they presents serious part of the pharmaceutical world 
market, where the top ten 10 Biopharmaceutical Companies (Fig 3) (2). 
The term „biosimilars” was introduced in March 2004, as the regulations stand, 
therapeutically similar products must be different to the original. As such, they cannot rely 
on the original data and must therefore submit full market authorisations via EMEA’s 
Centralised procedure (the obligatory or preferred route to market for most 
biopharmaceutical products). Most EMEA concept papers for biopharmaceutical medicinal 
products are directed to the active substance under patent expiry (3). 
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Source: IMS Health, BioGeneriX(1) 
Figure 1. Biopharmaceuticals’ share of global prescription sales 
 
 
Product Innovator 
company 
Active 
substance 
Patent 
expiration 
Global 
sales, 2002 
Humulin Lilly human 
insulin 
2001 $1.0bn 
Intron A Schering-
Plough 
Alpha-
interferon 
2002 $2.5bn 
Procrit Amgen/J&J erythropoietin 2004 $4.3bn 
Epogen Amgen erythropoietin 2004 $2.3bn 
Neupogen Amgen filgrastim 
(GCSF) 
2006 $1.4bn 
Source: IMS Health, BioGeneriX(1) 
Figure 2. Blockbuster biotechnology products with patent expiry before 2007 
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CASE STUDY 
Legislative basis of the “biosimilar” for marketing authorisation in EU  
The general requirements for generic products are not sufficient for biosimilar products 
because any changes in the manufacturing process may generate significant differences in 
terms of quality, safety, and efficacy. The efficacy and safety of a biosimilar biotech 
molecule is not necessarily to be the same for all indications.  Therefore, according to 
the pharmaceutical Review 2005, the applicants for biosimilar products will have to 
provide to EMEA specific preclinical and clinical data for each therapeutic indication and 
also for new routes of administration (4). 
 
Company                                                                               
Sales in  2006  
01 Amgen $13,858 
02 Genentech $7,640 
03 Novo Nordisk $6,526 
04 UCB Group $2,711 
05 Biogen Idec $2,592 
06 Gilead Sciences $2,588 
07 Serono $2,498 
08 Genzyme $2,278 
09 MedImmune $1,221 
10 Millennium $220 
 
Figure 3. Top 10 Biopharmaceutical Companies based on 2006 biopharma revenues 
Note: In all Top Company profiles, dollar amounts are in millions (2) 
 
 An abridged registration procedure which allows an applicant for marketing 
authorisation of a generic medicinal product to provide bioequivalence studies instead of 
necessary clinical trials. The manufacturer must prove the quality of the generic medicinal 
product and since the active substance is already well known for its safety and efficacy, the 
generic must only demonstrate its therapeutic equivalence to the reference product through 
what are known as bioequivalence studies.  
 No legal framework has existed for generic medicines derived from biotechnology 
before 2004. This deficiency was solved during the review of EU pharmaceutical 
legislation, known as the “Pharma Review 2005”. Specific provisions were adopted in the 
final text under the co-decision procedure by the European Council and the European 
Parliament establishing a legal base for biogenerics where “similar biological medicinal 
products“ are possible to be authorised under condition pointed in the Directive 
2004/27/EC.  
 The Commission published a new Directive 2004/27/EC (4) went into force on 1 
November 2005, introduced a legal framework for biosimilar medicines identical to that 
for generic medicines. Article 10(i) (iii) of the Directive 2001/83/EC together with Part II, 
section 4 of Annex 1 provided the guidelines for a biosimilar dossier.  
Biological medicinal products are defined in Part I 3.2.1.1 b. of Directive 
2003/63/EC with replace the Annex 1 of Directive 2001/83/EC. The definition in Article 
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10 (1) in 2001/83/EC was not applicable for the biological medicinal products and the 
concept for “Essential Similarity” was not possible to be used. The medicines legislation 
from 2004, amending the Community code on medicinal products for human use 
(Directive 2004/27/EC) Article 10, paragraph 4 introduces the requirements for biosimilars 
(4,5). 
The Directive 2004/27/EC which change the Community Code pointed in Art 15 
out what should be covered by the biological medicinal product similar to the referent 
product.  They couldn’t be taken as biogenerics because of differences in the 
manufacturing processes, used substance, molecular properties and the therapeutically 
efficacy. The final text of this new legislation was approved on 31 March 2004 by the 
Council and was transposed into national law and in effect throughout the EU by 
November 2005 (4). 
“Where a biological medicinal product which is similar to a reference biological 
product does not meet the conditions in the definition of generic medicinal products, 
owing to, in particular, differences relating to raw materials or differences in 
manufacturing processes of the biological medicinal product and the reference biological 
medicinal product, the results of appropriate pre-clinical tests or clinical trials relating 
to these conditions must be provided. The type and quantity of supplementary data to be 
provided must comply with the relevant criteria stated in Annex I and the related detailed 
guidelines. The results of other tests and trials from the reference medicinal product’s 
dossier shall not be provided” (4). 
The Directives 2001/83/EC and 2003/63/EG changed of specific marketing 
authorization application requirements, additional Modules 1, 2, 3 of the CTD format; 
particular the toxicological and clinic profile of Module 4 and 5 shall be provided. 
The practical approach depends on the analytical possibility in order to comply with 
the “biosimilarity” on the respective manufacturing process, on the clinical and regulatory 
experience. The approach could be used for well characterized biotech medicinal 
products, all recombinant DNA/Hybridomtechnic and all products with derivate and 
conjugate. As biopharmaceuticals are defined by their production process, any change can 
impact safety and efficacy and therefore demands new approval (5). 
Both the precise definition and the requirements for this therapeutic category in 
Article 10 (6) of Directive 2001/83/EC, as amended, have created a number of 
implications. The process for marketing authorization and preparation of biosimilar 
medicinal products is clearer and more precise than in the past, where even in case of a 
positive opinion of CHMP like INN Somatropin – trade name Omnitrop (London, 26 June 
2003, CPMP/3184/03) - no marketing authorization on Somatropin (Omnitrop) was 
granted by the Commission as Omnitrop was not considered to have well-established use 
and thus was not authorized till the Directive 2004/27/EC had come into force. Omnitrop 
was authorized later like a first biosimilar product authorized by the Community after 
Review 2005 was introduced and the Directive was already in place. During 2006 and 
2007 the number of submitted biosimilar applications to EMEA is 4 and 10 respectively.  
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Figure 4. Biosimilar application to EMEA 2006-2007 
 
 
The FDA legislation for “follow - on biologics” 
The U.S. FDA concedes that it has no framework for “follow-on biologics” for the 
vast majority of therapeutic proteins subject to biologic licensing under the Public Health 
Service Act.  The U.S. FDA concedes that it has no statutory framework for “follow-on 
biologics” for the vast majority of therapeutic proteins subject to biologic licensing under 
the Public Health Service Act. The U.S. agency builds a framework for a few large 
molecule products (human growth hormones, insulin etc.). An abbreviated process for 
limited types of biologics, types of tests to demonstrate structural similarity and 
comparability, immunogenicity testing requirements was outlined. Interchange ability for 
biologics represents a fundamentally more complex issue an approach and many 
guidelines were published. The FDA has pointed out concern for large comparative 
crossover studies for interchange ability rating and the acceptance of biosimilars by the 
medical community (6,7,8). 
 
 
Approaches dealt with comparability in the EMEA and ICH 
guidelines 
1. The comparability of biotechnical/biological products subjects to change in 
the manufacturing process in the clinical studies and after the marketing 
authorisation is subject of ICH guideline - ICH 5QE (10). 
The terms “comparability” has two aspects, in the ICH Guidelines 5QE refers to 
changes in the established manufacturing processes within the same manufacturer of an 
existing biotech medicinal products. In that case the requirements for demonstrating the 
comparability are not the same than for demonstrating similarity of biological product (10). 
 With Commission Regulation 1085/2003/EC and 1084/2003/EC stipulating the 
need for more costly lengthy and complex Type II variation, where simpler IA or IB 
procedure would be applicable for small molecule. When manufacturer introduce major 
changes and then the regulator may view the resulting protein as an entirely new medicinal 
product with need to demonstrate comparable safety and efficacy.  
1.1 The comparability of biotechnical/biological products subjects to change in the 
manufacturing process in the clinical studies (clinical development) 
Determinations of product comparability can be based on quality considerations 
whether the manufacturer can provide assurance of comparability through analytical 
studies. Additional evidence from nonclinical or clinical studies is considered appropriate 
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when quality data are insufficient to establish comparability.  The extent and nature of pre-
clinical and clinical studies will be determined on a case-by-case basis where various 
factors shall be considered. 
1.2. Demonstration of Comparability during Development   
 During product development, it is expected that multiple changes in the 
manufacturing process will occur that could impact drug product quality, safety, and 
efficacy. Comparability exercises are generally performed to demonstrate that pre-clinical 
and clinical data generated with pre-change product are applicable to post-change product 
in order to facilitate further development and support the marketing authorisation. 
Comparability studies conducted for products in development could be influenced by 
several of factors such as the stage of product development, the availability of validated 
analytical procedures, and the extent of product knowledge, which are limited at times due 
to the available experience that the manufacturer has with the process.  
 Comparability of biotechnological/biological products is required. The 
comparability exercise should utilise available information and will generally become 
more comprehensive.  Process changes introduced in late stages of development and when 
no additional clinical studies are planned to support the marketing authorisation, the 
comparability exercise should be as comprehensive uses method.  In that case some 
outcomes of the comparability studies on quality attributes can lead to additional non-
clinical or clinical studies.  
 Due to the limitations of the analytical steps in early clinical development, 
physicochemical and biological tests alone might be considered inadequate to determine 
comparability, and therefore, bridging pre-clinical and/or clinical studies, as appropriate, 
might be needed. In order for a comparability exercise to occur during development, 
appropriate assessment tools should be used and analytical procedures used during 
development might not be validated, but should provide results that are reliable and 
reproducible (10). 
 1.3. Preclinical and Clinical Considerations 
 Comparability determination can be based on quality considerations if the 
manufacturer can provide assurance of comparability through analytical studies and 
additional evidence from nonclinical or clinical studies is considered appropriate when 
quality data are insufficient to establish comparability. All non-clinical and clinical studies 
are determined on a case-by-case basis in consideration of different factors, which include 
quality findings, the nature and the level of knowledge of the product and existing non-
clinical and clinical data, relevant to the product (10,11). 
 2. The comparability of biotechnical/biological products subjects to change in 
the manufacturing process after the marketing authorisation (12) 
 A determination of comparability can be based on a combination of analytical 
testing, biological assays, and, in some cases, nonclinical and clinical data. If a 
manufacturer can provide assurance of comparability through analytical studies alone, 
nonclinical or clinical studies with the post-change product are not warranted. 
 Where the relationship between specific quality, safety and efficacy issues has not 
been established, and differences between quality of the pre- and post-change product are 
observed, it might be appropriate to include a combination of quality, nonclinical, and/or 
clinical studies in the comparability exercise.  
 The goal of the comparability exercise is to ensure the quality, safety and 
efficacy of drug product produced by a changed manufacturing process, through collection 
and evaluation of the relevant data to determine whether there might be any adverse impact 
on the drug product due to the manufacturing process changes.  
9 
 
 The demonstration of comparability does not mean that the quality issues of the 
pre-change and post-change product are identical, but that they are highly similar and that 
the existing knowledge could ensure that any differences in quality attributes have no 
adverse impact upon safety or efficacy of the product. To identify the impact of a 
manufacturing process change, a careful evaluation of all foreseeable consequences for the 
product should be performed.  
The quality data on the pre- and post-change product are generated, and a comparison 
is performed that integrates and evaluates all data collected, e.g.,  
− routine batch analyses;  
− in-process control; 
− process validation/evaluation data; 
− characterisation and stability, if appropriate. 
 
The comparison of the results to the predefined criteria should allow an objective 
assessment of whether or not the pre- and post-change products are comparable. The 
manufacturer could be faced with one of several outcomes, as follows:  
− No adverse impact on safety or efficacy profiles is foreseen- pre- and post-change 
product are highly similar and considered comparable;  
− The analytical procedures used are not sufficient to discern relevant differences 
that can impact the safety and efficacy of the product, additional testing (e.g., further 
characterisation) or nonclinical and/or clinical studies to reach a definitive 
conclusion should be performed; 
− Differences in the quality attributes of the pre-change and post-change product 
observed,  it can be justified that no adverse impact on safety or efficacy profiles is 
expected, based on the manufacturer’s accumulated experience, relevant information, 
and data. In these circumstances, pre- and post-change product can be considered 
comparable;  
− Comparison of quality attributes and a possible adverse impact on safety and 
efficacy profiles cannot be excluded and  the manufacturer should consider 
performing pre-clinical and/or clinical studies;  
− Differences in the quality attributes are so significant that it is determined that the 
products are not highly similar and are therefore not comparable.  
 
Pre-clinical or clinical data allows extrapolation of the existing data from the drug 
product produced by the current process to the drug product from the changed process. The 
products should have highly similar quality attributes biopharmaceutical product before 
and after manufacturing process changes and that there is no adverse impact on the safety 
or efficacy and immunogenicity, of the drug product occurred, based on an analysis of 
product quality attributes.  
 
 
Comparability to reference medicinal products of similar biological 
medicinal products is subject of the EMEA guidelines 
Biosimilar medicinal products are manufactured and controlled according to their own 
development. An extensive comparability exercise is required to demonstrate that the 
similar biological and reference products have similar attributes in terms of quality, safety 
and efficacy. The quality issues relevant for comparability presenting of similar biological 
medicinal products containing recombinant DNA-derived proteins are addressed in the 
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“Guideline on similar biological medicinal products containing biotechnology-derived 
proteins as active substances: quality issues” (EMEA/CHMP/49348/05) (13).  
 When an application for biological medicinal product is containing a 
biotechnology-derived medicinal protein as active substance it refers to a reference 
medicinal product having been granted a marketing authorisation by an independent 
applicant after the expiry of the data protection period in accordance with Title III Chapter 
I, Article 10 as the amended Directive 2001/83/EC (4). 
The Marketing Authorisation (MA) application dossier of a biological medicinal 
product claimed to be similar to a reference product already authorised shall provide a full 
Module 3 (quality dossier) and  equivalent efficacy and safety of the similar biological 
medicinal product has to be demonstrated as well. 
Biological medicines are usually complex and often heterogeneous, no modern 
analytical methodology may be adequate for full characterisation following process 
change. This is addressed in the released ICH and CHMP guidelines. The Directive  
2003/63/EC  and the guideline CHMP /BWP/49348/2005 stress that the impact of any 
process change need to be considered on a case-by case basis (5,11,13). 
This may involve merely testing against the finished product specification but, in 
many cases, additional extensive characterisation is required which may need to include 
non-clinical and clinical studies. According to the European guidelines, a manufacturer can 
claim that a new product is similar to a therapeutic protein already on the market. The 
claim should be substantiated concerning quality, safety and efficacy, which are the three 
main parts of a new drug application. For all three parts of the dossier - quality, safety and 
efficacy of the same innovator product should be used as a reference. 
Reference medicinal product is a medicinal product authorised in the EEA, on the 
basis of a complete dossier in accordance with the provisions of Article 8 of Directive 
2001/83/EC, as amended. The active substance of a similar biological medicinal product 
must be similar, in molecular and biological characteristic, to the active substance of the 
reference medicinal product. 
The same reference product should be used throughout the comparability program for 
quality, safety and efficacy studies during the development of a similar biological 
medicinal product in order to allow the generation of coherent data and conclusions. 
The pharmaceutical form, strength and route of administration of the similar 
biological medicinal product should be the same as that of the reference medicinal product 
and in case when the pharmaceutical form or the strength or the route of administration 
differ, the results of appropriate non-clinical/clinical trials must be provided in order to 
demonstrate the safety/efficacy of the similar biological medicinal product. Any 
differences between the similar biological medicinal product and the reference medicinal 
product will have to be justified by appropriate studies on a case-by-case basis.  
Reference Active Substance - the comparison of the biosimilar active substance to a 
publicly available standard as a reference (i.e. Ph.Eur, WHO, etc.) is not sufficient to 
demonstrate biosimilarity of the active substance since this material may not have known 
and defined safety and efficacy profiles and the manufacturer generally does not have 
access to the originator active substance, and cannot directly compare his active substance 
to the one used in the originator’s medicinal product.  Based on more than one analytical 
method the biosimilar manufacturer must demonstrate, that the active substance used in the 
comparability exercise is representative of the active substance present in the reference 
medicinal product.  
Applicant should use various approaches to obtain representative reference active 
substance derived from the reference medicinal product in order to perform the 
comparative analysis at the active substance level, where this approach should be 
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appropriately validated.  The suitability of the sample preparation process, and should 
include the comparison of the biosimilar active substance with active substance material 
derived from the reference and the biosimilar medicinal products (12). 
 
 
Comparability exercise for demonstrating biosimilarity - analytical 
methods for biosimilar medicinal products 
Characterisation studies “state-of-the-art” should be applied to the biosimilar and reference 
medicinal products in parallel at both the active substance and the medicinal product levels 
to demonstrate with a high level of assurance that the quality of the biosimilar product is 
comparable to the reference medicinal product. 
Analytical considerations - suitability of available analytical methods - Given the 
e complexity of the molecule and its inherent heterogeneity, the set of analytical techniques 
should represent the state-of-the-art and should be selected by the manufacturer in order to 
detect slight differences in the characteristics of the biotechnology-derived product and the 
selected methods used in the comparability exercise would be able to detect differences in 
all quality aspects.  
Biological activity - the comparability exercise should include an assessment of the 
biological properties of the similar biological medicinal product and the reference 
medicinal product. Biological assays using different approaches to measure the biological 
activity should be considered as appropriate. The results of relevant biological assay(s) 
should be provided and expressed in units of activity calibrated against an international or 
national reference standard, when available and appropriate and these assays should 
comply with appropriate European Pharmacopoeia requirements for biological assays, if 
applicable (10). 
Purity and impurities - the purity and impurity profiles of the active substance and 
medicinal product should be assessed both qualitatively and quantitatively by a 
combination of analytical procedures for both reference and biosimilar products. Tithe 
manufacturer developing biosimilar products would normally not have access to all 
necessary information that could allow a comparison with the reference medicinal product.  
Information provides conclusions on the purity and impurity profiles. The impurities in the 
biosimilar product should be identified and compared to the reference product using state-
of-the-art technologies and depending on the impurity it my be necessary to conduct trials 
in order to prove that there is no adverse impact of the surveyed biosimilar product. 
Specifications are defined as described in ICH Q6B: Note for Guidance on 
Specifications: Test Procedures and Acceptance Criteria for Biotechnological/Biological. 
(16)  The acceptance criteria should be described and  each acceptance criteria should be 
established and justified based on data obtained from lots used in nonclinical and/or 
clinical studies, and by data from lots used for the demonstration of manufacturing 
consistency, data from stability studies, relevant development data and data obtained from 
the comparability exercise (quality, safety and efficacy). 
 The goal of the comparability exercise is to ensure the quality, safety and efficacy 
of drug product produced by a changed manufacturing process, through collection and 
evaluation of the relevant data to determine whether there might be any adverse impact on 
the drug product due to the manufacturing process changes. 
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Conclusion 
The demonstration of comparability does not necessarily mean that the quality attributes of 
the pre-change and post-change product are identical, but that they are highly similar and 
that the existing knowledge is sufficiently predictive to ensure that any differences in 
quality attributes have no adverse impact upon safety or efficacy of the drug product. 
Although in Europe a regulatory path for approval of “biogenerics” was no longer 
possible, before end 2005 the regulatory path of biosimilars is directed to demonstrate 
considerable quality pre-clinical and clinical data.  
The Regulatory authorities are breaking new grounds in regards with the biosimilar 
products. The balanced approach adopted by EMEA regarding the additionally published 
guidelines for biosimilars after Directive 2004/27/EC will allow evaluation on a case by 
case basis and the well defined framework can be built up on the based of the scientific 
knowledge.  
The extent and the nature of non-clinical tests and clinical studies on biosimilar 
products are determined in consideration of various factors. According to Review 2005, 
many guidelines specifying the “appropriate pre-clinical tests or clinical trials” clarifying 
the general requirements for biological products in terms of safety and efficacy are issued. 
Nonetheless, there are still many questions about the data required to demonstrate 
biosimilarity with a biological reference product and how companies will manage after 
having received scientific advice by EMEA and new additional guidelines: 
− Immunogenicity assessment of biotechnology-derived therapeutic proteins 
(guideline) Biosimilar medicinal products containing recombinant interferon alpha 
(guideline) 
− Biosimilar medicinal products containing low molecular weight heparins (guidelines) 
are available (17). 
 
 
EXERCISE 
Task 1 
Please provide the approaches dealt with comparability in the EMEA and ICH guidelines. 
 
Task 2 
Please provide where the definition for biosimilar is published and what is the difference 
between generic and biosimilar product. 
 
Task 3 
Please provide the main issues for comparability of biosimilar medicinal products. 
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